Proactive Investors - Run By Investors For Investors

Harvest One Cannabis names Frank Holler chairman as Peter Wall remains on the board

The cannabis company is tapping a veteran in biotechnology, investment banking and venture capital
A woman holding a marijuana plant
Last month, the cannabis company posted record quarterly revenue

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) said Friday that it has named Frank Holler, a biotechnology, investment banking and venture capital industry veteran, as its chairman

The Vancouver-based company said in the press release that former Chairman Peter Wall will remain on the board.

READ: Harvest One Cannabis posts record revenue, enjoying boost from Dream Water subsidiary

Holler is president and CEO of Vancouver-based Ponderosa Capital Inc and previously held CEO roles at Lions Capital Corp, Xenon Pharmaceuticals Inc and ID Biomedical Corp. He was a founding director of Angiotech Pharmaceuticals, a Toronto Stock Exchange- and Nasdaq-listed medical device company that was sold in 2017.

Before working in biotechnology and health care, Holler was an investment banker at Merrill Lynch Canada.

"Frank's experience, particularly in the pharmaceutical industry and capital markets, strengthens the depth of expertise on the Harvest One board,” Harvest One CEO Grant Froese said.

Shares of Harvest One climbed C$0.01 to C$0.42 in Friday’s Canadian trading. They fetched US$0.32 on the OTC Markets.

Last month, the company posted record quarterly revenue driven by its Dream Water product line, acquired in May.

 

Contact Dennis Fitzgerald at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full HVT profile View Profile

Harvest One Cannabis Inc Timeline

Related Articles

Woman holding cannabis leaf
October 15 2018
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
Laboratory testing
October 09 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 30 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use